Type 1 diabetes mellitus: Primary, secondary, and tertiary prevention

Mount Sinai Journal of Medicine

Volumn 75, Issue 4, 2008, Pages 385-397

  Bollyky, Jennifer ^a   Sanda, Srinath ^a,b   Greenbaum, Carla J ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

Autoimmunity; Clinical trial; Prevention; Type 1 diabetes

Indexed keywords

ABATACEPT; ALUMINUM HYDROXIDE; AUTOANTIBODY; B7 ANTIGEN; CD28 ANTIGEN; CD3 ANTIBODY; CD40 ANTIGEN; COD LIVER OIL; CYCLOSPORIN; DACLIZUMAB; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65; GLUTEN; INSULIN; INSULIN AUTOANTIBODY; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEGA 3 FATTY ACID; PANCREAS ISLET CELL ANTIBODY; PLACEBO; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TEPLIZUMAB; THYMOCYTE ANTIBODY; TRX 4; UNCLASSIFIED DRUG; VITAMIN D;

ANTIGEN PRESENTING CELL; AUTOIMMUNITY; CELL GROWTH; CEREAL; CLINICAL TRIAL; DIABETES CONTROL; DIARRHEA; DIET SUPPLEMENTATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TARGETING; FOOD INTAKE; GASTROINTESTINAL TOXICITY; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC REGULATION; MILK; PANCREAS ISLET BETA CELL; PRIMARY PREVENTION; PROPHYLAXIS; REHABILITATION; REVIEW; RISK FACTOR; SECONDARY PREVENTION;

AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; PRIMARY PREVENTION; RISK FACTORS; SECONDARY PREVENTION;

EID: 52649156076     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20054     Document Type: Review

References (85)

1. Dittrich HM. History of the discovery of pancreatic diabetes by von Mering and Minkowski 1889. A historical overview on the occasion of the 100th anniversary [in German]. Z Gesamte Inn Med 1989; 44: 335-340.
2. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 2: 1279-1283.
3. MacCuish A, Barnes E, Irvine W, Duncan L. Antibodies to islet cells in insulin-dependent diabetics with coexistent autoimmune disease. Lancet 1974; 2: 1529-1531.
4. Palmer J, Asplin C, Clemons P. Insulin autoantibodies in insulin-dependent diabetes before insulin treatment. Science 1983; 222: 1337-1339.
5. Baekkeskov S, Aanstoot H, Christgau S, et al. Identification of the 64kD autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347: 151-156.
6. Lu J, Li Q, Xie H, et al. Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proc Natl Acad Sci U S A 1996; 93: 2307-2311.
7. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007; 104: 17 040-17 045.
8. Foulis AK. The pathology of the endocrine pancreas in type 1 (insulin-dependent) diabetes mellitus. Apmis 1996; 104: 161-167.
9. Gepts W. Pathology and anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965; 14: 619-633.
10. Kim SJ, Holbeck SL, Nisperos B, et al. Identification of a polymorphic variant associated with HLA-DQw3 and characterized by specific restriction sites within the DQ beta-chain gene. Proc Natl Acad Sci U S A 1985; 82: 8139-8143.
11. Menser MA, Forrest JM, Honeyman MC, Burgess JA. Letter: diabetes, HL-A antigens, and congenital rubella. Lancet 1974; 2: 1508-1509.
12. Nerup J, Platz P, Andersen OO, et al. HL-A antigens and diabetes mellitus. Lancet 1974; 2: 864-866.
13. Ganda OP, Srikanta S, Brink SJ, et al. Differential sensitivity to beta-cell secretagogues in "early," type I diabetes mellitus. Diabetes 1984; 33: 516-521.
14. Bleich D, Jackson RA, Soeldner JS, Eisenbarth GS. Analysis of metabolic progression to type I diabetes in ICA+ relatives of patients with type I diabetes. Diabetes Care 1990; 13: 111-118.
15. Srikanta A, Ganda OP, Gleason RE, et al. Pre-type I diabetes: linear loss of beta cell response to intravenous glucose. Diabetes 1984; 33: 717-720.
16. Faber O. Beta-cell function and diabetic control in insulin dependent diabetes mellitus. Acta Endocrinol Suppl (Copenh) 1985; 272: 73-77.
17. Hoogwerf BJ, Rich SS, Barbosa JJ. Meal-stimulated C-peptide and insulin antibodies in type I diabetic subjects and their nondiabetic siblings characterized by HLA-DR antigens. Diabetes 1985; 34: 440-445.
18. Scholin A, Bjorklund L, Borg H, et al. Islet antibodies and remaining beta-cell function 8 years after diagnosis of diabetes in young adults: a prospective follow-up of the nationwide Diabetes Incidence Study in Sweden. J Intern Med 2004; 255: 384-391.
19. Incidence and trends of childhood type 1 diabetes worldwide 1990-1999. Diabet Med 2006; 23: 857-866.
20. Harjutsalo V, Podar T, Tuomilehto J. Cumulative incidence of type 1 diabetes in 10,168 siblings of Finnish young-onset type 1 diabetic patients. Diabetes 2005; 54: 563-569.
21. Karvonen M, Viik-Kajander M, Moltchanova E, et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000; 23: 1516-1526.
22. Lammi N, Taskinen O, Moltchanova E, et al. A high incidence of type 1 diabetes and an alarming increase in the incidence of type 2 diabetes among young adults in Finland between 1992 and 1996. Diabetologia 2007; 50: 1393-1400.
23. Passa P. Diabetes trends in Europe. Diabetes Metab Res Rev 2002; 18(suppl 3): S3-S8.
24. TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr Diabetes 2007; 8: 286-298.
25. Hermann R, Knip M, Veijola R, et al. Temporal changes in the frequencies of HLA genotypes in patients with type 1 diabetes-indication of an increased environmental pressure? Diabetologia 2003; 46: 420-425.
26. Gillespie KM, Bain SC, Barnett AH, et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 2004; 364: 1699-1700.
27. Barker JM, Barriga KJ, Yu L, et al. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004; 89: 3896-3902.
28. Kimpimaki T, Kupila A, Hamalainen AM, et al. The first signs of beta-cell autoimmunity appear in infancy in genetically susceptible children from the general population: the Finnish Type 1 Diabetes Prediction and Prevention Study. J Clin Endocrinol Metab 2001; 86: 4782-4788.
29. Schenker M, Hummel M, Ferber K, et al. Early expression and high prevalence of islet autoantibodies for DR3/4 heterozygous and DR4/4 homozygous offspring of parents with type I diabetes: the German BABYDIAB study. Diabetologia 1999; 42: 671-677.
30. Virtanen SM, Saukkonen T, Savilahti E, et al. Diet, cow's milk protein antibodies and the risk of IDDM in Finnish children. Childhood Diabetes in Finland Study Group. Diabetologia 1994; 37: 381-387.
31. Norris JM, Beaty B, Klingensmith G, et al. Lack of association between early exposure to cow's milk protein and beta-cell autoimmunity. Diabetes Autoimmunity Study in the Young (DAISY). JAMA 1996; 276: 609-614.
32. TRIGR Study Group. Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR). Pediatr Diabetes 2007; 8: 117-137.
33. Norris JM, Barriga K, Klingensmith G, et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA 2003; 290: 1713-1720.
34. Ziegler AG, Schmid S, Huber D, et al. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 2003; 290: 1721-1728.
35. Fuchtenbusch M, Ziegler AG, Hummel M. Elimination of dietary gluten and development of type 1 diabetes in high risk subjects. Rev Diabet Stud 2004; 1: 39-41.
36. Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr 1999; 70: 560S-569S.
37. Litherland SA, Xie XT, Hutson AD, et al. Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus. J Clin Invest 1999; 104: 515-523.
38. Stene LC, Joner G. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am J Clin Nutr 2003; 78: 1128-1134.
39. Mathieu C, Badenhoop K. Vitamin D and type 1 diabetes mellitus: state of the art. Trends Endocrinol Metab 2005; 16: 261-266.
40. Adorini L. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol 2005; 233: 115-124.
41. Wicklow BA, Taback SP. Feasibility of a type 1 diabetes primary prevention trial using 2000 IU vitamin D3 in infants from the general population with increased HLA-associated risk. Ann N Y Acad Sci 2006; 1079: 310-312.
42. Diabetes Prevention Trial Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346: 1685-1691.
43. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 2005; 28: 1068-1076.
44. Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT: a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004; 363: 925-931.
45. Greenbaum CJ, Cuthbertson D, Krischer JP. Type I diabetes manifested solely by 2-h oral glucose tolerance test criteria. Diabetes 2001; 50: 470-476.
46. Sosenko JM, Palmer JP, Greenbaum CJ, et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006; 29: 643-649.
47. Diabetes Control and Complications Trial. Henry Ford Hosp Med J 1983; 31: 115-116.
48. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294-2303.
49. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26: 832-836.
50. Sjoberg S, Gjotterberg M, Berglund L, et al. Residual C-peptide excretion is associated with a better long-term glycemic control and slower progress of retinopathy in type I (insulin-dependent) diabetes mellitus. J Diabet Complications 1991; 5: 18-22.
51. Shevach EM. Regulatory T cells in autoimmunity. Annu Rev Immunol 2000; 18: 423-449.
52. Ziegler AG, Hillebrand B, Rabl W, et al. On the appearance of islet associated autoimmunity in offspring of diabetic mothers: a prospective study from birth. Diabetologia 1993; 36: 402-408.
53. Harrison LC, Honeyman MC, Steele CE, et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004; 27: 2348-2355.
54. Harrison L, Chu X, DeAizpurua H, et al. Islet reactive T cells are a marker of preclinical insulin-dependent diabetes. J Clin Invest 1992; 89: 1161-1165.
55. Peakman M, Tree TI, Endl J, et al. Characterization of preparations of GAD65, proinsulin, and the islet tyrosine phosphatase IA-2 for use in detection of autoreactive T-cells in type 1 diabetes: report of phase II of the Second International Immunology of Diabetes Society Workshop for Standardization of T-cell assays in type 1 diabetes. Diabetes 2001; 50: 1749-1754.
56. Pinkse GG, Boitard C, Tree TI, et al. HLA class I epitope discovery in type 1 diabetes: independent and reproducible identification of proinsulin epitopes of CD8 T cells-report of the IDS T Cell Workshop Committee. Ann N Y Acad Sci 2006; 1079: 19-23.
57. Ke Y, Pearce K, Lake JP, et al. Gamma delta T lymphocytes regulate the induction and maintenance of oral tolerance. J Immunol 1997; 158: 3610-3618.
58. Weiner HL. Treatment of autoimmune diseases by oral tolerance to autoantigens. Autoimmunity 1993; 15: 6-7.
59. Weiner HL, Friedman A, Miller A, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994; 12: 809-837.
60. Simell O. Proc Immunol Diabetes Soc 2007 unpublished report from Immunology of Diabetes Society meeting presentation.
61. Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003; 52: 1128-1136.
62. Agardh CD, Cilio CM, Lethagen A, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005; 19: 238-246.
63. Bekris LM, Jensen RA, Lagerquist E, et al. GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination. Diabet Med 2007; 24: 521-526.
64. Peakman M, Stevens EJ, Lohmann T, et al. Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4. J Clin Invest 1999; 104: 1449-1457.
65. Bensinger SJ, Walsh PT, Zhang J, et al. Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol 2004; 172: 5287-5296.
66. Tian L, Lu L, Yuan Z, et al. Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery. Transplantation 2004; 77: 183-189.
67. Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, et al. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 2002; 51: 638-645.
68. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994; 91: 123-127.
69. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54: 1763-1769.
70. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346: 1692-1698.
71. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-2608.
72. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996; 39: 1005-1029.
73. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.
74. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998; 128: 517-523.
75. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 2005; 1: 22-31.
76. Brand SJ, Tagerud S, Lambert P, et al. Pharmacological treatment of chronic diabetes by stimulating pancreatic beta-cell regeneration with systemic co-administration of EGF and gastrin. Pharmacol Toxicol 2002; 91: 414-420.
77. Suarez-Pinzon WL, Yan Y, Power R, et al. Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes 2005; 54: 2596-2601.
78. Meier JJ, Butler AE, Galasso R, et al. Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans. Diabetologia 2006; 49: 2689-2696.
79. Greenbaum CJ. Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials. Clin Immunol 2002; 104: 97-104.
80. Pozzilli P. Immuno-intervention and preservation of beta-cell function in type 1 diabetes. Diabetes Metab Res Rev 2007; 23: 255-256.
81. Skyler JS. Prediction and prevention of type 1 diabetes: progress, problems, and prospects. Clin Pharmacol Ther 2007; 81: 768-771.
82. Staeva-Vieira T, Peakman M, von Herrath M. Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 2007; 148: 17-31.
83. Assan R, Feutren G, Sirmai J, et al. Plasma C-peptide levels and clinical remissions in recent-onset type I diabetic patients treated with cyclosporin A and insulin. Diabetes 1990; 39: 768-774.
84. Stiller CR, Laupacis A, Dupre J, et al. Cyclosporine for treatment of early type I diabetes: preliminary results. N Engl J Med 1983; 308: 1226-1227.
85. Stiller CR, Dupre J, Gent M, et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984; 223: 1362-1367.